These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 11489837

  • 1. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 2. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS, Cho-Chung YS.
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [Abstract] [Full Text] [Related]

  • 3. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS.
    Clin Cancer Res; 2005 Aug 15; 11(16):5950-5. PubMed ID: 16115938
    [Abstract] [Full Text] [Related]

  • 4. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Jun 15; 6(6):2506-12. PubMed ID: 10873106
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Nov 15; 6(11):4343-50. PubMed ID: 11106252
    [Abstract] [Full Text] [Related]

  • 6. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS.
    Clin Cancer Res; 2002 Feb 15; 8(2):607-14. PubMed ID: 11839683
    [Abstract] [Full Text] [Related]

  • 7. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.
    Clin Cancer Res; 2003 Feb 15; 9(2):866-71. PubMed ID: 12576461
    [Abstract] [Full Text] [Related]

  • 8. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
    Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS.
    Clin Cancer Res; 2000 Sep 15; 6(9):3434-41. PubMed ID: 10999726
    [Abstract] [Full Text] [Related]

  • 9. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 10. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello F.
    Clin Cancer Res; 1999 Apr 15; 5(4):875-81. PubMed ID: 10213224
    [Abstract] [Full Text] [Related]

  • 11. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Dec 15; 7(12):4156-63. PubMed ID: 11751516
    [Abstract] [Full Text] [Related]

  • 12. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
    Nesterova MV, Cho-Chung YS.
    Clin Cancer Res; 2004 Jul 01; 10(13):4568-77. PubMed ID: 15240549
    [Abstract] [Full Text] [Related]

  • 13. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

  • 14. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE.
    Cancer Res; 2002 Apr 01; 62(7):2034-42. PubMed ID: 11929822
    [Abstract] [Full Text] [Related]

  • 15. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O, Hacker NF, Cho-Chung YS.
    Oncogene; 1999 Sep 02; 18(35):4999-5004. PubMed ID: 10490835
    [Abstract] [Full Text] [Related]

  • 16. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.
    Clin Cancer Res; 2003 Oct 01; 9(12):4595-605. PubMed ID: 14555535
    [Abstract] [Full Text] [Related]

  • 17. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May 01; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 18. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
    Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI, Dalgleish AG.
    Cancer Res; 2003 Feb 01; 63(3):593-9. PubMed ID: 12566301
    [Abstract] [Full Text] [Related]

  • 19. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ.
    Urol Oncol; 2011 Feb 01; 29(4):421-9. PubMed ID: 19576799
    [Abstract] [Full Text] [Related]

  • 20. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.
    Clin Cancer Res; 2006 Aug 15; 12(16):4940-8. PubMed ID: 16914583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.